SCHEDULE: Ikarian Capital Discloses 21.2% Stake in Tenax Therapeutics
Beneficial Ownership Report
Ikarian Capital and Neil Shahrestani have reported a 21.2% beneficial ownership stake in Tenax Therapeutics, Inc., holding 967,600 shares of common stock.
Summary
- Ikarian Capital, LLC and Neil Shahrestani jointly reported beneficial ownership of 967,600 shares of Tenax Therapeutics, Inc. common stock.
- This represents 21.2% of the company's outstanding common stock.
- The ownership is held through Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts managed by Ikarian Capital.
- The filing date is October 7, 2025, with the event date requiring the filing being September 30, 2025.
- The percentage is based on 4,562,500 shares outstanding as of August 11, 2025, as disclosed in Tenax Therapeutics' quarterly report on Form 10-Q.
Sentiment
Score: 6
Explanation: This is a neutral filing, primarily a disclosure of a significant passive ownership stake. The substantial percentage (21.2%) by an institutional investor could be viewed positively by some, indicating confidence, but the filing itself is factual and non-promotional.
Positives
- A significant institutional investor, Ikarian Capital, LLC, and its principal, Neil Shahrestani, have disclosed a substantial 21.2% ownership stake in Tenax Therapeutics, Inc., indicating notable institutional interest.
Future Outlook
NA
Management Comments
- The reporting persons certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Tenax Therapeutics, Inc., nor in connection with any transaction having such purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.
Industry Context
This filing indicates significant institutional investor interest in Tenax Therapeutics, Inc., a company operating in the healthcare/biotechnology sector. A substantial stake by an investment adviser like Ikarian Capital can signal confidence in the company's long-term prospects within its industry.
Stakeholder Impact
- Shareholders: Increased transparency regarding significant institutional ownership. Potential for increased investor confidence due to a large stake held by an investment adviser.
Key Dates
| Date | Description |
|---|---|
| 2025-08-11 | Date as of which 4,562,500 shares of Common Stock were outstanding, as disclosed in the Issuer's Form 10-Q. |
| 2025-08-13 | Date Tenax Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2025. |
| 2025-09-30 | Date of event requiring the filing of this statement. |
| 2025-10-07 | Date the Schedule 13G was signed and filed. |
Recommendation
holdThe filing indicates a substantial 21.2% passive ownership by Ikarian Capital, LLC and Neil Shahrestani in Tenax Therapeutics. While this demonstrates significant institutional interest, the Schedule 13G is a disclosure of a passive stake, not an active investment thesis or operational update. Investors should view this as a signal of institutional confidence but await further operational or financial updates from Tenax Therapeutics before making more aggressive investment decisions. The 'hold' recommendation reflects the neutral but potentially positive signal of significant institutional backing without new fundamental company information.
Keywords
Tenax Therapeutics, Ikarian Capital, Neil Shahrestani, Schedule 13G, beneficial ownership, common stock, institutional investor, healthcare, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.